期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肾素-血管紧张素系统与糖尿病肾病 被引量：6

原文传递
导出
摘要 随着社会经济的发展、生活水平的提高、生活方式的改变，糖尿病发病率在全球范围内迅速上升；而随着糖尿病诊治技术的不断进步，糖尿病患者的生存时问显著延长，使糖尿病肾病（DN）的患病率也逐年上升。目前，在美国和欧洲许多国家糖尿病肾病已成为引发终末期肾衰竭（ESRD）的首要原因。但其发生机制尚未完全明确，目前认为是多因素作用的结果，其中肾素一血管紧张素系统（RAS）的作用一直是研究的热点，且血管紧张素转换酶抑制药（ACEI）或血管紧张素受体阻断药（ARB）的疗效和合理应用也是临床关注的焦点。现就肾素一血管紧张素系统及其介导的糖尿病肾病机制综述如下。
作者 邹健 田丰 孙圣燕 宋海峰
机构地区 解放军
出处 《人民军医》 2012年第1期68-70,共3页 People's Military Surgeon
关键词 肾素 血管紧张素 糖尿病肾病
分类号 R587.2 [医药卫生—内分泌]
  • 相关文献

参考文献14

  • 1Unger T. The ngiotensin type 2 receptor: Variations on enigmatic themes[J]. Hypertension, 1997,17(12 Pt 2):1775-1786.
  • 2MarsoS,SternD,著.张代富,主译.糖尿病与心血管疾病[M].北京:人民卫生出版社,2006.
  • 3郑芬萍,李红.血管紧张素Ⅱ与糖尿病肾病的关系[J].国外医学（内分泌学分册）,2002,22(1):19-21. 被引量：17
  • 4Pippin J, Bain SC, Barnett AH,et al. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study[J]. J Diabetes Complications, 2002,16(3) : 195-200.
  • 5Brenner BM,Cooper ME,de Zeeuw D,et al. The losartan renal pro tection study-rationale, study design and baseline eharaetefistiesof RENAAL(reduction of endpoints in NIDDM with the angiotensin II antagonist losanan) [J]. J Renin Angiotensin Aldosterone Syst, 2000, 1(4) :328-335.
  • 6Lewis EJ, Hunsicker LG, Clarke WR,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in. patients with ne- phropathy due to type 2 diabetes[J]. New Engl J Med, 2001,345(12):851-860.
  • 7Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes[J]. New Engl J Meal,2001,345(12) :861 869.
  • 8Agntwal R, Siva S, Dunn SR, et al. Add-on Angiotensin Ⅱ Receptor blockadee lower surinary transforming growth factor-beta levels [J]. Am J Kidney Dis,2002,39(3) :486-492.
  • 9Ruggenenti P, bassi A, Ilieva AP, et al. Preventing rnicroalbuminuria in type 2 diabetes[J]. New Engl J Med,2004,351(19) :1941-1951.
  • 10De Zeeuw D, Remuzzi G, Parving H H, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy :Lessons from RENAAL[J]. Kidney Int, 2004,65 (6) : 2309 2320.

二级参考文献17

  • 1Mizuiri S,Yoshikawa H,Tanegashima M,et al.Renal ACE immunohistochemical location in NIDDM patients with nephropathy[J].Am J Kidney,1998,31:301-307.
  • 2Lai K N,Leung J C,Lai K B,et al.Gene expression of the renin-angiotensin system in human kidney[J].J Hypertens,1998,16:91-102.
  • 3Wagner J,Gehlen F,Ciechanowicz A,et al.Angiotensin Ⅱ receptor typeⅠgene expression in human glomerulonephritis and diabetes mellitus[J].J Am Soc Nephrol,1999,10:545-551.
  • 4Leehey D J,Singh A K,Alavi N,et al.Role of angiotensin Ⅱ in DN[J].Kidney Int,2000,58:s93-s98.
  • 5Thaiss F,Wolf G,Assad N,et al.Angiotensinase A gene expression and enzyme activity in isolated glomeruli of diabetic rats[J].Diabetologia,1996,39:275-280.
  • 6Hirano T,Kashiwazaki K,Moritomo Y,et al.Albuminuria is directly associated with increased plasma PAI-1 and factor Ⅷ levels in NIDDM patients[J].Diabetes Res Clin Pract,1997,36:11-18.
  • 7Kagami S,Kuhara T,Okada K,et al.Dual effects of angiotensin Ⅱ in the plasminogen/plasmin system in rat mesangial cells[J].Kidney Int,1997,51:664-671.
  • 8Motojima M,Kakuchi J,Yoshioka T,et al.Association of TGF-beta singnaling in angiotensin Ⅱ-induced PAI-1 mRNA upregulation in mesangial cells:role of PKC[J].Biochim Biophys Acta,1999,1449:217-226.
  • 9Rovin B H,Doe N,Tan L C,et al. Monocyte chemoattractant protein 1 levels in patients with glomerular disease[J].Am J Kidney Dis,1996,27:640-646.
  • 10Saitoh A,Sekizuka K,Hayashi T,et al. Detection of urinary MCP-1 in patients with diabetic nephropathy[J].Nephron,1998,80:99.

共引文献16

同被引文献55

  • 1徐柏颐.黄蜀葵花醇提物治疗家兔系膜增殖性肾炎的实验研究[J].江苏中医,1996,17(3):42-44. 被引量：27
  • 2刘志红.糖尿病肾病的治疗[J].中国实用内科杂志,2006,26(3):322-323. 被引量：102
  • 3Wu C, Lu H, Cassis LA, et al. Molecular and pathophysiological features of angiotensinogen: a mini review [J]. N Am J Med Sei (Boston) ,2011,4(4) :183-190.
  • 4Yiannikouris F, Karounos M, Charnigo R, et al. Adipocyte- specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice[J]. Am J Physiol Regul Integr Comp Physiol, 2012,302 (2) :244-245.
  • 5Li XC. Genetic deletion of ATla receptors attenuates intracellular accumulation of ANG in the kidney of AT1 a receptor-defident mice[J]. Am J Physiol Renal Physiol, 2007, 293(1) :586-593.
  • 6Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin mediated cardiovascular and renal diseases[J]. Pharmacol Rev, 2000,52 (1) : 11-34.
  • 7Urushihara M, Kondo S, Kagami S, et al. Urinary angiotensinogen accurately re{leers intrarenal renin-angiotensin system activity[J].Am J Nephrol,2010,31(1) :321-322.
  • 8Kobori H, Nishiyama A, Harrison-Bernard LM, et al. Urinaryangiotensinogen as an indicator o[ intrarenal angiotensin status in hypertension[J]. Hypertension, 2003,41 (1) : 42-49.
  • 9Kobori H, Nishiyama A. Effects of tempol on renal angiotensinogen production in Dahl salt-sensitive rats [J]. Biochem Biophys Res Commun,2004,315(3):746-750.
  • 10Modrall JG,Sadjadi J, Brosnihan KB, et al. Depletion of tissueangiotensin converting enzyme differentially influences the intrarenal and urinary expression of angiotensin peptides[J]. Hypertension, 2004,43 (2) : 849-853.

引证文献6

二级引证文献24

人民军医
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部